Loading…
SMS Pharmaceuticals (SMSPHARMA)₹513.20+1.62%Pharmaceuticals
In the Jun 2026 quarter (consolidated), SMS Pharmaceuticals reported sales of ₹207 Cr, up 5.6% from Jun 2025, and net profit of ₹21.04 Cr, up 4.9% year on year. For the year to Mar 2026, sales were ₹886 Cr and net profit ₹102 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| Expenses | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 |
| Operating Profit | 27.99 | 28.98 | 33.98 | 33.99 | 30.98 | 33.01 | 40.98 | 39.01 | 47.99 | 43.99 | 39.99 | 40.99 |
| OPM % | 17.1% | 18.1% | 14.1% | 20.1% | 16.1% | 19.1% | 16.1% | 20.1% | 20.1% | 21.1% | 17.1% | 20.1% |
| Other Income | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 1.99 | 0.99 | 0.99 | 0.99 | 3.99 | 2.99 | 1.99 |
| Interest | 5.99 | 5.99 | 5.99 | 4.99 | 4.99 | 3.99 | 4.99 | 5.99 | 5.99 | 6.01 | 4.99 | 5.99 |
| Depreciation | 7.97 | 7.98 | 7.98 | 7.97 | 8.98 | 8.97 | 8.97 | 9.97 | 9.97 | 9.96 | 9.97 | 9.98 |
| Profit before tax | 14.99 | 16.98 | 21.99 | 21.99 | 20.01 | 21.99 | 29.01 | 23.99 | 34.01 | 30.98 | 27.01 | 27.01 |
| Tax % | 21.0% | 26.0% | 26.0% | 25.0% | 29.0% | 24.0% | 30.0% | 23.0% | 26.0% | 26.0% | 23.0% | 26.0% |
| Net Profit | 12.04 | 11.03 | 17.05 | 16.05 | 14.05 | 18.05 | 20.05 | 20.05 | 25.05 | 23.06 | 33.08 | 21.04 |
| EPS (Rs) | 1.39 | 1.37 | 2.05 | 1.96 | 1.67 | 2.16 | 2.30 | 2.32 | 2.71 | 2.52 | 3.50 | 2.24 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 610 | 437 | 462 | 464 | 411 | 562 | 519 | 521 | 708 | 782 | 886 | 896 |
| Expenses | 521 | 362 | 368 | 374 | 331 | 441 | 404 | 466 | 592 | 643 | 715 | 724 |
| Operating Profit | 88.98 | 74.93 | 92.93 | 89.91 | 80.03 | 121 | 115 | 54.99 | 117 | 139 | 171 | 173 |
| OPM % | 15.1% | 17.1% | 20.1% | 19.1% | 19.1% | 22.1% | 22.1% | 10.1% | 16.1% | 18.1% | 19.1% | 19.3% |
| Other Income | 3.98 | 0.99 | 1.99 | 2.99 | 4.98 | 2.99 | 4.98 | 4.98 | 3.99 | 5.98 | 7.97 | 9.96 |
| Interest | 17.01 | 15.99 | 14.98 | 11.99 | 11.99 | 10.99 | 19.01 | 21.99 | 23.99 | 18.98 | 22.98 | 22.98 |
| Depreciation | 18.94 | 18.93 | 19.95 | 18.93 | 21.94 | 21.92 | 31.88 | 31.88 | 31.92 | 33.90 | 39.88 | 39.88 |
| Profit before tax | 56.01 | 41.99 | 60.01 | 61.94 | 50.97 | 91.01 | 67.96 | 4.99 | 65.98 | 92.01 | 117 | 119 |
| Tax % | 26.0% | 14.0% | 33.0% | 34.0% | 36.0% | 33.0% | 1.0% | 28.0% | 26.0% | 27.0% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 41.13 | 28.06 | 32.07 | 40.11 | 32.06 | 63.15 | 62.20 | −7.02 | 50.15 | 69.18 | 102 | 102 |
| EPS (Rs) | 4.84 | 3.37 | 3.76 | 4.74 | 3.74 | 7.39 | 7.36 | −0.84 | 5.89 | 7.81 | 10.90 | 10.97 |
| Dividend payout % | 4.0% | 6.0% | 7.0% | 5.0% | 7.0% | 4.0% | 4.0% | −36.1% | 7.0% | 5.0% | 4.0% | — |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.01 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.01 | 8.01 | 8.02 | 9.02 | 9.02 |
| Reserves | 285 | 246 | 277 | 314 | 341 | 403 | 463 | 452 | 529 | 632 | 777 |
| Borrowings | 205 | 149 | 147 | 145 | 158 | 256 | 264 | 255 | 282 | 312 | 366 |
| Other Liabilities | 159 | 89.42 | 72.35 | 93.45 | 103 | 148 | 127 | 166 | 218 | 203 | 213 |
| Total Liabilities | 658 | 494 | 505 | 561 | 610 | 814 | 862 | 882 | 1,037 | 1,156 | 1,366 |
| Fixed Assets | 371 | 291 | 280 | 282 | 281 | 458 | 439 | 413 | 438 | 535 | 536 |
| CWIP | 13.01 | 8.01 | 8.01 | 18.01 | 42.02 | 7.01 | 11.01 | 33.02 | 29.99 | 35.03 | 122 |
| Investments | 21.07 | 29.11 | 28.10 | 27.09 | 26.09 | 27.11 | 22.07 | 11.05 | 11.05 | 12.05 | 26.09 |
| Other Assets | 253 | 166 | 188 | 233 | 260 | 322 | 390 | 425 | 558 | 575 | 683 |
| Inventories | 113 | 93.18 | 107 | 136 | 129 | 138 | 252 | 225 | 234 | 286 | 352 |
| Trade receivables | 60.93 | 20.99 | 23.99 | 25.99 | 48.98 | 106 | 48.99 | 148 | 236 | 203 | 216 |
| Cash & equivalents | 14.94 | 11.96 | 12.96 | 14.94 | 9.96 | 40.87 | 46.84 | 6.98 | 35.88 | 41.84 | 45.83 |
| Total Assets | 658 | 494 | 505 | 561 | 610 | 814 | 862 | 882 | 1,037 | 1,156 | 1,366 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 60.79 | 72.72 | 31.90 | 49.83 | 39.90 | 89.77 | 44.88 | 21.92 | 49.84 | 81.81 | 58.79 |
| Cash from investing activity | −96.99 | −38.97 | −16.98 | −34.98 | −42.99 | −152 | −26.98 | −29.99 | −51.99 | −123 | −131 |
| Cash from financing activity | 27.01 | −32.99 | −14.99 | −13.01 | −1.99 | 91.91 | −12.01 | −31.97 | 30.99 | 46.96 | 76.01 |
| Net cash flow | −8.99 | 0.99 | 0.00 | 1.99 | −4.99 | 30.98 | 5.99 | −39.01 | 28.99 | 4.99 | 3.99 |
| Capex | 88.87 | 22.98 | 8.99 | 34.97 | 42.97 | 152 | 26.99 | 29.96 | 51.94 | 123 | 131 |
| Free cash flow | −26.89 | 49.79 | 22.90 | 14.93 | −2.99 | −60.81 | 17.93 | −6.98 | −1.99 | −41.85 | −70.71 |
| CFO / OP % | 93.0% | 110.0% | 46.0% | 70.0% | 65.0% | 88.0% | 52.0% | 50.1% | 56.0% | 73.0% | 49.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 37 | 19 | 20 | 21 | 44 | 69 | 35 | 105 | 123 | 96 | 90 |
| Inventory days | 105 | 113 | 134 | 169 | 190 | 147 | 332 | 242 | 200 | 237 | 259 |
| Days payable | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 95 | 89 |
| Cash conversion cycle | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 237 | 260 |
| Working capital days | 20 | −1 | 28 | 40 | 58 | 49 | 95 | 105 | 86 | 89 | 99 |
| ROCE % | — | 13.1% | 18.1% | 17.0% | 13.0% | 17.1% | 13.1% | 4.0% | 12.1% | 13.0% | 13.0% |
For the Jun 2026 quarter, SMS Pharmaceuticals reported sales of ₹207 Cr, up 5.6% year on year and net profit of ₹21.04 Cr, up 4.9% year on year. The operating margin was 20.1%.
SMS Pharmaceuticals' sales for the year to Mar 2026 were ₹886 Cr; over the last twelve months they were ₹896 Cr.
Net profit for the year to Mar 2026 was ₹102 Cr, and ₹102 Cr over the last twelve months. Earnings per share over the same trailing period were ₹10.97.
SMS Pharmaceuticals reported borrowings of ₹366 Cr at Mar 2026, against cash and equivalents of ₹45.83 Cr.
Cash from operations was ₹58.79 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹70.71 Cr.